In this article, we will be taking a look at the 10 Best Mid Cap Stocks to Invest In According to Billionaires.
Venu Krishna, Managing Director and Head of U.S. Equity Strategy at Barclays, talked about the recent market increase and the implications for investors on April 2. He said that while markets negotiate a highly complex geopolitical environment, ongoing macroeconomic and political concerns are testing the rally’s strength.
The anticipated duration and results of the Middle East conflict, which continue to impact investor confidence and risk appetite, are one of the primary sources of uncertainty that have been influencing the mood. Despite these worries, Krishna pointed out that historically, the majority of significant conflicts over the previous fifteen years have not escalated globally, and geopolitical shocks have tended to remain confined. Based on this perspective, he predicted that the S&P 500 index might reach 7,650, which shows both durability and underlying volatility in the larger market environment, if American consumption declines and impedes global development.
He also stressed on the fact that investors should concentrate on scenario-based planning rather than responding to everyday news. He claims that despite keeping a careful eye on vital factors like energy prices, changes in global demand, and the quality of company balance sheets, positioning for relative U.S. market strength is still crucial. According to him, the current rise seems to reflect market hopes of a relatively swift resolution to geopolitical tensions, but in such uncertain times, it is crucial to preserve cash flow flexibility and give priority to financially sound companies.
Recently, trading sessions have shown signs of market turbulence. The Dow Jones Industrial Average entered correction territory on March 27 when U.S. stocks plummeted due to increased oil prices. The Nasdaq Composite fell 2.1%, worsening its decline due to a global tech sell-off, while the S&P 500 fell about 1.7%, marking its longest losing streak since 2022 with five consecutive weeks of losses.
Sentiment is still heavily influenced by changes in the price of oil. Liz Ann Sonders, Chief Investment Strategist at Charles Schwab, said on CNBC’s “Closing Bell” on March 26 that “we’re still very much at the mercy of oil,” which emphasizes how stocks are still susceptible to shocks to the energy market. In the meantime, Jill Carey Hall of BofA Securities predicts that small- and mid-cap companies will beat mega-cap names this year, indicating a possible continuation of a larger bull cycle and an early shift in market leadership.
With that said, let’s take a look at the best mid cap stocks.
Our Methodology
For our methodology, we screened stocks with mid-cap market capitalizations between $2 billion and $10 billion that showed upside potential. From this filtered universe, we selected the top 10 stocks based on the latest news and developments. We then ranked these stocks according to the number of billionaire holdings, as tracked by the Insider Monkey database. In cases where stocks had the same number of billionaire holdings, we used market capitalization as a tiebreaker to determine their final ranking.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
Here is our list of the 10 best mid cap stocks to invest in according to billionaires.
10. Bitdeer Technologies Group (NASDAQ:BTDR)
Number of Billionaire Holdings: 9
Market cap: $2.61 billion
Bitdeer Technologies Group (NASDAQ:BTDR) is one of the best mid cap stocks on our list.
TheFly reported on April 9 that Cantor Fitzgerald lowered its rating on BTDR from Overweight to Neutral and reduced its price target to $10 from $20. The firm noted that while BTDR is pursuing multiple initiatives, including Bitcoin mining, ASIC production, and AI-related services, concerns are growing among investors about management’s ability to successfully carry out these plans.
Moreover, on April 7, Bitdeer Technologies Group (NASDAQ:BTDR) introduced its new SEALMINER A4 series of Bitcoin mining machines, powered by its in-house developed SEAL04 chips. The lineup includes three variants: A4 Pro Air, A4 Pro Hydro, and A4 Ultra Hydro, built to support different operating environments through both air and hydro cooling systems. The machines are designed to deliver strong performance with improved energy efficiency, reaching as low as 9.45 J/TH, while maintaining stable operation for large-scale mining activities.
The systems also focus on reducing downtime and ensuring consistent output. Additionally, hydro-cooling technology supports effective heat control in dense setups while maintaining low noise levels. This launch reflects the company’s ongoing focus on advancing its technology roadmap and strengthening its mining infrastructure capabilities through continued research and development efforts.
Bitdeer Technologies Group (NASDAQ:BTDR) is a global technology company specializing in cryptocurrency mining and AI infrastructure. It provides hash rate sharing, cloud mining, and data center solutions, leveraging proprietary hardware and scalable energy-efficient operations.
9. ImmunityBio, Inc. (NASDAQ:IBRX)
Number of Billionaire Holdings: 9
Market cap: $7.72 billion
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best mid cap stocks.
TheFly reported on April 9 that IBRX reported preliminary first-quarter 2026 net product revenue of about $44.2 million, exceeding the consensus estimate of $43.17 million. Its lead therapy, ANKTIVA, has secured approvals or authorizations across five regulatory regions, covering roughly 34 countries.
The company also confirmed that enrollment for its key BCG-naive CIS study has been completed, with the monitoring committee determining that no further participants are needed. A supplemental biologics license application remains planned for submission in 2026. As of March 31, 2026, ImmunityBio, Inc. (NASDAQ:IBRX) held approximately $380.9 million in cash, cash equivalents, and marketable securities. The company continues to focus on expanding its presence in the U.S. while increasing its reach across international markets.
In a separate move, on April 6, IBRX responded to a communication from the FDA’s Office of Prescription Drug Promotion concerning issues identified on March 13 related to a podcast and a television advertisement. The company clarified that the advertisement referenced had never been broadcast and confirmed that the podcast content in question has been removed, with steps taken to eliminate it from external platforms. It also outlined corrective measures, including stricter internal review processes, enhanced compliance protocols, and additional oversight to ensure future promotional materials meet regulatory standards.
ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage biotechnology company developing immunotherapies to treat cancer and infectious diseases. Its platform focuses on activating the immune system using novel cell and vaccine-based approaches to improve long-term patient outcomes.
